Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Direct observations: clinical cases, poisoning incidents and other

Currently viewing:

Administrative data

direct observations: clinical cases, poisoning incidents and other
Type of information:
experimental study
Adequacy of study:
supporting study
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
study well documented, meets generally accepted scientific principles, acceptable for assessment

Data source

Reference Type:

Materials and methods

Study type:
study with volunteers
Endpoint addressed:
basic toxicokinetics
Test guideline
no guideline followed
Principles of method if other than guideline:
- Principle of test: Oral administration of the test item to healthy human volunteers
- Parameters analysed / observed: Quantification of total lipids anf free fatty acids, quantification of CLA and its metabolites
GLP compliance:

Test material

Constituent 1
Reference substance name:
Reference substance 001
Test material form:


Type of population:
- Number of subjects exposed: 27
- Sex: male/female
- Age: > 30, < 40 years
Ethical approval:
confirmed, but no further information available
Route of exposure:
Reason of exposure:
Exposure assessment:
Details on exposure:
A capsule which contained 1 g of 80 % CLA (63 % c9t11, 13 % t10,c12, 3 % cll,t13), 14 % oleic acid, 3 % linoleic acid and 5 % palmitic acid) was given daily for two months.
Group 1 served as control with no CLA supplement.
• Group 2 was assigned to a dietary intake of 0.8 g/d CLA
• Group 3 was assigned to a dietary intake of 1.6 g/d CLA
• Group 4 was assigned to a dietary intake of 3.2 g/d CLA
- Other:
Quantification of total lipids and free fatty acids and of CLA and its metabolites in blood samples.

Results and discussion

Any other information on results incl. tables

The plasma concentration of c9,t11 CLA increased linearly 3-, 6- and 11-fold, with respect to unsupplemented controls, following dietary supplementation with 0.8, 1.6 or 3.2 g/d of CLA intake, respectively. The metabolites of c9,t11 CLA after delta 6 desaturation (CD 18:3) increased 1.5-, 2- and 4- fold with respect to unsupplemented controls, while CD 20:3 reached a plateau at 4-fold increase after 1.6 g/d CLA intake. The peroxisomal beta oxidation product, CD 16:2, increased of 1.5-, 2- and -3 fold in plasma. The ratio be tween the plasma value of CD 16:2 and CLA which indicates the peroxisomal beta oxidation ratio, decreased linearly up to 1.6 g/d CLA intake, and stabilised at this level of CLA intake. CLA supplementation between 0.8 and 3.2 g/d did not cause any significant changes in plasma cholesterol levels. After two months wash out period, plasma levels of CLA returned to basal levels, for all levels of dietary CLA supplementation.

Applicant's summary and conclusion